Compare HNVR & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNVR | CRBU |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.5M | 166.6M |
| IPO Year | 2022 | 2021 |
| Metric | HNVR | CRBU |
|---|---|---|
| Price | $25.01 | $1.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $24.50 | $10.75 |
| AVG Volume (30 Days) | 54.4K | ★ 2.4M |
| Earning Date | 04-27-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.72% | N/A |
| EPS Growth | N/A | ★ 3.64 |
| EPS | ★ 0.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.49 | $1.63 |
| Revenue Next Year | $8.61 | $10.93 |
| P/E Ratio | $99.16 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.91 | $1.38 |
| 52 Week High | $25.61 | $3.53 |
| Indicator | HNVR | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 62.24 | 35.14 |
| Support Level | $22.09 | $1.39 |
| Resistance Level | $25.61 | $1.73 |
| Average True Range (ATR) | 0.68 | 0.11 |
| MACD | 0.08 | -0.01 |
| Stochastic Oscillator | 75.82 | 0.94 |
Hanover Bancorp Inc is a community commercial bank focused on providing personalized and efficient services and products tailored to local needs. The Bank offers a full range of financial services, including a complete suite of consumer, commercial, and municipal banking products such as multifamily and commercial mortgages, government-guaranteed loans, residential loans, business loans, and lines of credit. In addition, it provides customers with access to 24-hour ATM services with no fees, interest-bearing free checking accounts, telephone banking, mobile and internet banking solutions for both consumer and business clients, and safe deposit boxes.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.